by Lyla El-Fayomi | Sep 12, 2024
Welcome to a special edition of my blog that summarizes all the big news from the summer. I hope you’ve all been able to soak up (safely) as much sun as possible. Below, I cover the latest in aging, global trends in clinical trials for engineered biomaterials,...
by Peace Chukwu | Sep 5, 2024
From extracting insulin from the pancreas of cows to extreme diets and herbal remedies for glucose regulation, diabetes treatments over the century have evolved progressively, with each discovery extending the life span of patients a little longer than the last....
by Kevin Robb | Aug 22, 2024
Last month, the U.S. Food and Drug Administration (FDA) agreed to formally review a revised Biologics License Application (BLA) from Mesoblast for their mesenchymal stromal cell (MSC) product, remestemcel-L. The submission represents the third attempt by the company...
by Lyla El-Fayomi | Jun 18, 2024
“Regenerative medicine news under the microscope” is a monthly feature highlighting a selection of impactful research findings and headlines across the many subfields of regenerative medicine. Throughout the past month, I’ve spotted some notable trends emerging in the...
by Lyla El-Fayomi | May 23, 2024
“Regenerative medicine news under the microscope” is a monthly feature highlighting a selection of impactful research findings and headlines across the many subfields of regenerative medicine. I’ve gone slightly longer form with this month’s edition, as I found that...
by Stacey Johnson | Feb 23, 2024
As a fair-skinned, freckled person (my mom says she painted them on me while I slept), and one who has a family history of skin cancers and melanoma, the news on February 19 that Iovance Biotherapeutics’ AMTAGVITM received U.S. Food and Drug Administration (FDA)...
Comments